Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
75.07
-0.10 (-0.13%)
Streaming Delayed Price
Updated: 1:21 PM EDT, Apr 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
↗
March 31, 2025
Via
Benzinga
Ionis to present at upcoming investor conferences
March 31, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Competitive Analysis In The ATTR-CM Field
↗
March 30, 2025
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...
Via
Talk Markets
Topics
Stocks / Equities
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
March 26, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
What Analysts Are Saying About Ionis Pharmaceuticals Stock
↗
March 11, 2025
Via
Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
↗
February 20, 2025
Via
Benzinga
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
↗
March 12, 2025
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.
Via
Benzinga
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
March 11, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
March 10, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For February 19, 2025
↗
February 19, 2025
Via
Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
↗
January 15, 2025
Via
Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
↗
December 20, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
↗
November 07, 2024
Via
Benzinga
Ionis to present at upcoming investor conferences
February 25, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
February 20, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharma Beats Expectations for Q4
↗
February 19, 2025
The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss.
Via
The Motley Fool
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
↗
February 19, 2025
Ionis Pharmaceuticals posted a smaller-than-expected Q4 loss and exceeded revenue estimates. The company projects 2025 revenue of over $600 million.
Via
Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
↗
November 07, 2024
Via
Benzinga
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
↗
September 26, 2024
Via
Benzinga
Ionis reports fourth quarter and full year 2024 financial results
February 19, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to hold fourth quarter and full year 2024 financial results webcast
February 05, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
January 23, 2025
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA
From
Biogen Inc.
Via
GlobeNewswire
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
↗
January 07, 2025
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.
Via
Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
↗
January 07, 2025
One analyst says the six-month study was too short and the benefits could appear over time.
Via
Investor's Business Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
↗
January 03, 2025
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Via
Benzinga
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
↗
December 20, 2024
Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
November 12, 2024
Via
Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
↗
October 31, 2024
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
↗
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via
Investor's Business Daily
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
October 08, 2024
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
